Le Lézard2d
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...
Morningstar2d
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet – Phase 1 Data Indicate Potential for Use of Once ...
BioSpace3d
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
– Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – – Also at CROI: New PURPOSE 1 Data Showcasing Preference for ...
News-Medical.Net on MSN1d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Gilead price target raised to $130 from $123 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...
Business Wire2d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
News Medical2d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor ...
Le Lézard1d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...
Unveiling Pharma Market Potential: DelveInsight's Strategic Insights into the Rapidly Expanding MASH Landscape in Asia
DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...